A new CRISPR-mediated Apc knockout allele leads to pyloric gland adenoma-like gastric polyps in mice with C57BL/6;FVB/N mixed background

Abstract

Adenomatous polyposis coli (APC) mutations are the most frequently identified genetic alteration in sporadic colorectal cancer (CRC) cases, and a myriad of genetically engineered Apc-mutant CRC mouse models have been developed using various genetic manipulation techniques. The advent of the CRISPR/Cas9 system has revolutionized the field of genetic engineering and facilitated the development of new genetically engineered mouse models. In this study, we aimed to develop a novel Apc knockout allele using the CRISPR/Cas9 system and evaluate the phenotypic effects of this new allele in two different mouse strains. For this purpose, exon 16 of mouse Apc gene was targeted with a single-guide RNA, and the mouse carrying an Apc frameshift mutation at codon 750 (Δ750) was chosen as the founder. The mutant FVB-Apc^Δ750 mice were backcrossed with wild-type C57BL/6 mice, and the phenotypic effects of the knockout allele were evaluated in F8-FVB-Apc^Δ750, F4-B6;FVB-Apc^Δ750, and F1-B6;FVB-Apc^Δ750 by a macroscopic and microscopic examination of the gastrointestinal system. The result showed that the mean polyp number was significantly higher in F4-BL6;FVB-Apc^Δ750 than in F8-FVB-Apc^Δ750. Intestinal polyposis was more prominent in F4-BL6;FVB-Apc^Δ750, whereas a higher number of colon polyps than intestinal polyps were observed in F8-FVB-Apc^Δ750. Additionally, F1-BL6;FVB-Apc^Δ750 mixed background mice developed gastric polyps that morphologically resembled the pyloric gland adenoma of humans. In conclusion, we developed a novel CRISPR-mediated Apc knockout allele using two mouse strains. We showed that this allele can exert a strain-specific effect on the phenotype of mice and can cause gastric polyp formation.

Keywords

adenomatous polyposis coli (APC) / colorectal cancer / mouse model / pyloric gland adenoma

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011; 6(1): 479-507.

[3] The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.

[4] Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: past, present and future perspectives. World J Gastroenterol. 2020; 26(13): 1394-1426.

[5] Jackstadt R, Sansom OJ. Mouse models of intestinal cancer. J Pathol. 2016; 238(2): 141-151.

[6] Stastna M, Janeckova L, Hrckulak D, Kriz V, Korinek V. Human colorectal cancer from the perspective of mouse models. Genes (Basel). 2019; 10(10): 788.

[7] Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet. 2005; 6(6): 507-512.

[8] Carbery ID, Ji D, Harrington A, et al. Targeted genome modification in mice using zinc-finger nucleases. Genetics. 2010; 186(2): 451-459.

[9] Sung YH, Baek IJ, Kim DH, et al. Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol. 2013; 31(1): 23-24.

[10] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096): 816-821.

[11] Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013; 153(4): 910-918.

[12] Weber J, Rad R. Engineering CRISPR mouse models of cancer. Curr Opin Genet Dev. 2019; 54: 88-96.

[13] Roper J, Tammela T, Cetinbas NM, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol. 2017; 35(6): 569-576.

[14] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121): 819-823.

[15] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research. 1988; 16(3): 1215.

[16] Akyol A, Güner G, Özşeker HS, et al. An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues. Lab Investig. 2019; 99(1): 128-137.

[17] Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990; 247(4940): 322-324.

[18] Zeineldin M, Neufeld KL. More than two decades of Apc modeling in rodents. Biochim Biophys Acta Rev Cancer. 2013; 1836(1): 80-89.

[19] Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A. 1995; 92(10): 4482-4486.

[20] Ren J, Sui H, Fang F, Li Q, Li B. The application of Apc^Min/+ mouse model in colorectal tumor researches. J Cancer Res Clin Oncol. 2019; 145(5): 1111-1122.

[21] Li C, Lau HCH, Zhang X, Yu J. Mouse models for application in colorectal cancer: understanding the pathogenesis and relevance to the human condition. Biomedicine. 2022; 10(7): 1710.

[22] Hamilton BA, Yu BD. Modifier genes and the plasticity of genetic networks in mice. PLoS Genet. 2012; 8(4): e1002644.

[23] Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol. 1992; 116(6): 1517-1526.

[24] Dietrich W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 1993; 75(4): 631-639.

[25] McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract. 2008; 204(7): 479-490.

[26] Moser AR, Hegge LF, Cardiff RD. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Cancer Res. 2001; 61(8): 3480-3485.

[27] Svendsen C, Alexander J, Knutsen HK, Husøy T. The min mouse on FVB background: susceptibility to spontaneous and carcinogen-induced intestinal tumourigenesis. Anticancer Res. 2011; 31(3): 785-788.

[28] Wang S, Kuang J, Li G, et al. Gastric precancerous lesions present in Apc^Min/+ mice. Biomed Pharmacother. 2020; 121: 109534.

[29] Wood LD, Salaria SN, Cruise MW, Giardiello FM, Montgomery EA. Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms. Am J Surg Pathol. 2014; 38(3): 389-393.

[30] Brosens LAA, Wood LD, Offerhaus GJ, et al. Pathology and genetics of syndromic gastric polyps. Int J Surg Pathol. 2016; 24(3): 185-199.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.